Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to evaluate whether transcranial direct current stimulation (tDCS) and cognitive rehabilitation can improve cognitive functions and neuronal plasticity in patients with multiple sclerosis (MS). The participant population consists of MS patients (both sexes, adults), who commonly experience cognitive impairment in addition to physical and psychological symptoms.
The main questions it aims to answer are:
Does tDCS applied over the left dorsolateral prefrontal cortex improve cognitive abilities in MS patients?
Does the combination of tDCS and cognitive rehabilitation enhance neuroplasticity, as measured by DTI, BDNF levels, and acetylcholinesterase activity?
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| tDCS | Experimental | A 30-minute tDCS session with the cathode placed over the left dorsolateral prefrontal cortex (DLPFC) |
|
| tDCS+Cognitive training | Experimental | A 30-minute tDCS session with the cathode over the left DLPFC combined with computer-based cognitive rehabilitation training |
|
| Sham tDCS | Sham Comparator | Sham stimulation applied over the left DLPFC, mimicking the sensation of tDCS without delivering active current |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| tDCS | Device | A 30-minute tDCS session with the cathode placed over the left dorsolateral prefrontal cortex (DLPFC), delivered in 10 sessions over 2 weeks. This protocol targets cognitive improvement in MS patients |
| Measure | Description | Time Frame |
|---|---|---|
| Change in verbal memory performance measured by California Verbal Learning Test-II (CVLT-II) | The CVLT-II assesses verbal learning and memory through a word recall task. Scores include total recall, short-delay recall, and long-delay recall. Assessments will be conducted at baseline and after 4 weeks of intervention. | Baseline and immediately after 10 intervention sessions |
| Change in attention performance measured by Integrated Visual and Auditory Continuous Performance Test (IVA-2) | The IVA-2 evaluates visual and auditory attention and response control. Scores include full-scale attention quotient, visual attention, auditory attention, and response control. Assessments will be conducted at baseline and post-intervention to assess changes in attention performance | Baseline and immediately after 10 intervention sessions |
| Change in visuospatial memory performance measured by Rey-Osterrieth Complex Figure Test | The Rey-Osterrieth Complex Figure Test evaluates visuospatial constructional ability and memory. Participants copy a complex figure (copy trial) and then reproduce it from memory immediately and after a delay. Assessments will be conducted at baseline and after completion of the tDCS intervention to assess changes in visuospatial memory performance. | Baseline and immediately after 10 intervention sessions |
| Change in serum BDNF levels (ng/mL) | Serum brain-derived neurotrophic factor (BDNF) concentration will be measured using an enzyme-linked immunosorbent assay (ELISA). Blood samples will be collected at baseline and after completion of the tDCS intervention. Changes in BDNF levels will be analyzed to assess neuroplasticity. | Baseline and immediately after 10 intervention sessions |
| Change in white matter integrity measured by Diffusion Tensor Imaging (DTI) |
Not provided
Not provided
Inclusion Criteria:
Age between 20 and 50 years.
Diagnosed with relapsing-remitting multiple sclerosis (RRMS).
Mild disability, defined as EDSS < 5.
Patients who attended the neurology clinic and are willing to participate.
Exclusion Criteria:
Presence of psychiatric disorders requiring treatment with neuroleptics.
History of seizures.
Left-handed individuals.
Recent MS relapse requiring steroid treatment.
Pregnant women.
History of brain surgery or presence of intracranial clips.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shahid Beheshti University of Medical Science | Tehran | Iran |
Data will be made available to qualified researchers. Data sharing will occur after the publication of the primary study results. Requests for data access will be considered on a case-by-case basis and can be initiated by contacting the corresponding author. Data will be shared under a data use agreement to ensure appropriate use and confidentiality
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D065908 | Transcranial Direct Current Stimulation |
| D000091942 | Cognitive Training |
| ID | Term |
|---|---|
| D004599 | Electric Stimulation Therapy |
| D013812 | Therapeutics |
| D003295 | Convulsive Therapy |
| D013000 | Psychiatric Somatic Therapies |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cognitive Rehabilitation | Device | computer-based cognitive rehabilitation exercises. Conducted in 10 sessions over 2 weeks to enhance attention, memory, and neuroplasticity in MS patients. |
|
| Sham tDCS | Device | Sham stimulation applied over the left DLPFC for 30 minutes, mimicking the sensation of tDCS without delivering active current, over 10 sessions, used as control to blind participants to the intervention |
|
White matter integrity will be assessed using DTI MRI scans. Primary metrics include Fractional Anisotropy (FA) and Mean Diffusivity (MD) in predefined brain regions. Scans will be performed at baseline and after completion of the tDCS intervention to evaluate neuroplasticity-related changes
| Baseline and immediately after 10 intervention sessions |
| Change in acetylcholinesterase (AChE) activity in blood (U/mL) | Acetylcholinesterase activity will be measured in blood samples using a spectrophotometric enzymatic assay. Samples will be collected at baseline and after completion of the tDCS intervention. Changes in AChE activity will be analyzed to assess cholinergic system function and neuroplasticity. | Baseline and immediately after 10 intervention sessions |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D004191 | Behavioral Disciplines and Activities |
| D004597 | Electroshock |
| D011580 | Psychological Techniques |
| D000066530 | Neurological Rehabilitation |
| D012046 | Rehabilitation |
| D000359 | Aftercare |
| D003266 | Continuity of Patient Care |
| D005791 | Patient Care |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |